Doximity, Inc. Share Price Target ‘$29.85’, now 4.8% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Doximity, Inc. with ticker code (DOCS) now have 13 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The range between the high target price and low target price is between $35.00 and $24.00 with the average share target price sitting at $29.85. (at the time of writing). Given that the stocks previous close was at $28.49 this now indicates there is a potential upside of 4.8%. The 50 day MA is $28.69 and the 200 moving average now moves to $26.98. The company has a market capitalization of 5.23B. The stock price is currently at: $28.02 USD

The potential market cap would be $5,476,770,930 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.82, revenue per share of $2.44 and a 9.91% return on assets.

Doximity, Inc. provides a digital platform for United States (U.S) medical professionals. The Company’s cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with medical news and research, and manage careers. The Company supports physicians in practice of medicine with mobile and clinical workflow tools, such as voice and video telehealth, secure messaging and digital faxing. The Company’s platform offers marketing, hiring, and telehealth solutions. Its marketing solutions enable pharmaceutical and health system customers to get content, services, and peer connections to medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms. Its telehealth solutions consist of software tools that include voice and video dialers, designed to connect patients with care providers.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Dr. Martens (LON:DOCS) reports first half results aligning with expectations, highlighting strategic progress in marketing, cost reduction, and U.S. growth.

      Search

      Search